SPK Acquisition Corp.: directors' dealings · United States · SEC (Form 4)

About SPK Acquisition Corp.

SPK Acquisition Corp. is a United States-listed special purpose acquisition company (SPAC) trading on the NASDAQ. In practical terms, SPK is not a traditional operating business but a publicly listed acquisition vehicle created to identify, negotiate, and complete a merger or similar business combination with one or more private companies. The company was incorporated in Delaware on December 31, 2020, and its IPO closed on June 10, 2021. The units later began trading separately on or about July 23, 2021, following the usual SPAC structure of splitting units into common stock and rights. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1848097/000157570522000174/spk_10k.htm?utm_source=openai)) From a business-model standpoint, SPK’s core function is to raise capital, hold the IPO proceeds in a trust account, and then deploy that capital through a qualifying transaction such as a merger, share exchange, asset acquisition, stock purchase, recapitalization, or reorganization. SEC filings make clear that the company was formed for exactly that purpose, and that the trust proceeds were intended to remain protected until either a business combination was completed or the SPAC was required to liquidate. This means SPK’s “operations” are essentially transactional rather than commercial. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1848097/000157570522000174/spk_10k.htm?utm_source=openai)) A major strategic milestone came in 2022, when SPK entered into a merger agreement with Varian Biopharmaceuticals, Inc., a private Florida-based precision oncology company developing novel cancer therapies. SEC materials indicate that the combined company was expected to list on NASDAQ under the proposed ticker “VBIO.” That transaction context is important because it places SPK squarely in the healthcare/biopharma ecosystem, even though the SPAC itself has no product line of its own. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1848097/000157570522000133/spk_425.htm?utm_source=openai)) In competitive terms, SPK should be evaluated as a SPAC platform rather than as a conventional issuer with revenues, margins, or a branded product portfolio. Its competitive advantage lies in the speed and flexibility of the de-SPAC route, which can be attractive for private companies seeking public-market access. Its weaker points are the usual SPAC risks: dependence on sponsor execution, deal approval, shareholder redemptions, financing certainty, and the ability to satisfy listing requirements after the merger. SEC disclosures also highlight the possibility of liquidation if no transaction is completed within the required time frame. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1848097/000157570522000529/sc14a.htm?utm_source=openai)) Geographically, SPK is a United States company organized under Delaware law and regulated through SEC reporting, with a NASDAQ market listing. Historical SEC filings also show a business address in Shanghai, suggesting that parts of the sponsor or administrative setup were linked to China, but the issuer itself remains a U.S. public company. For investors in France, Belgium, or Switzerland, the key takeaway is that SPK is a deal-driven U.S. listed SPAC whose fundamental value depends on the quality of the target and the outcome of the pending or historical combination process. Recent items to monitor are SEC filings, insider Form 4 activity, and any fresh announcement regarding extensions, merger execution, or wind-up actions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1848097/000157570522000174/0001575705-22-000174-index.htm?utm_source=openai))